IntVal Achieves Pilot Scale Production Breakthrough with Tetradecylthioacetic Acid (TTA)
Shanghai IntVal Chemicals successful conducted the first pilot scale production for Tetradecylthioacetic Acid (TTA), a synthetic fatty acid analog with significant potential in metabolic disease therapeutics and anti-inflammatory applications. The milestone marks a critical step toward commercializing TTA for clinical and research markets.
Manufacturing Breakthrough
Leveraging advanced synthetic process, IntVal’s proprietary process achieves > 99% purity with 95% yield. The production facility, located in Hubei Province, utilizes the real-time monitoring of reaction kinetics—a cross-industry innovation adapted from high-precision manufacturing. This integration enables granular control over temperature, pressure, and catalytic efficiency, ensuring batch-to-batch consistency at scale.
Scientific and Industrial Impact
TTA's mechanism—activating PPARα/γ nuclear receptors to regulate lipid metabolism and inflammation—has shown promise in preclinical studies for treating non-alcoholic fatty liver disease (NAFLD) and insulin resistance. Until now, supply constraints limited research to kg-scale trials. IntVal's ton-scale capacity unlocks:
Commercial partnerships with pharmaceutical firms pursuing TTA-based formulations;
Strategic Vision Scaling TTA production bridges the gap between academic discovery and application in firms.The company aims to allocate 30% of initial output to academic collaborations, prioritizing metabolic and aging research.
The facility's modular design allows rapid expansion to 10-ton annual capacity, aligning with growing demand from the metabolic health sector, projected to help thousandes of the potential consumers of severe obesity
IntVal Achieves Pilot Scale Production Breakthrough with Tetradecylthioacetic Acid (TTA)
Shanghai, China — Shanghai IntVal Chemicals has successfully completed its first pilot-scale production of Tetradecylthioacetic Acid (TTA), a synthetic fatty acid analog with significant potential in metabolic disease therapeutics and anti-inflammatory applications. This milestone marks a critical step toward commercializing TTA for clinical and research markets.
Manufacturing Breakthrough
Leveraging an advanced proprietary synthesis process, IntVal achieved >99% purity with 95% yield at its Hubei Province facility. The production line integrates real-time reaction kinetics monitoring—an innovation adapted from high-precision manufacturing—enabling granular control over temperature, pressure, and catalytic efficiency. This ensures consistent batch-to-batch quality at scale.
Scientific and Industrial Impact
TTA's mechanism activates PPARα/γ nuclear receptors to regulate lipid metabolism and inflammation, showing promise in preclinical studies for treating non-alcoholic fatty liver disease (NAFLD) and insulin resistance. Previously limited to kg-scale trials due to supply constraints, IntVal's pilot-scale capacity now enables:
● Commercial partnerships with pharmaceutical firms developing TTA-based formulations;
● Expanded preclinical studies for regulatory submissions.
Strategic Vision
"Scaling TTA production bridges the gap between academic discovery and commercial application," stated a company representative. IntVal will allocate 30% of initial output to academic collaborations, prioritizing metabolic and aging research.
Expansion Roadmap
The facility's modular design allows rapid scaling to 10-ton annual capacity, aligning with growing demand from the metabolic health sector. This expansion aims to support thousands of potential patients suffering from severe obesity and related metabolic disorders.